Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 6 | 2018 | 420 | 1.190 |
Why?
|
| HIV-1 | 6 | 2018 | 706 | 1.030 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 63 | 1.020 |
Why?
|
| HIV Infections | 18 | 2015 | 2303 | 1.000 |
Why?
|
| Substance Abuse, Intravenous | 6 | 2009 | 121 | 0.900 |
Why?
|
| Puerto Rico | 28 | 2017 | 1378 | 0.890 |
Why?
|
| Hepatitis C | 4 | 2006 | 125 | 0.760 |
Why?
|
| Proteoglycans | 1 | 2018 | 47 | 0.630 |
Why?
|
| Viral Load | 3 | 2015 | 312 | 0.620 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 62 | 0.620 |
Why?
|
| Curcumin | 2 | 2015 | 74 | 0.610 |
Why?
|
| Virus Replication | 1 | 2018 | 278 | 0.550 |
Why?
|
| Viremia | 1 | 2015 | 42 | 0.530 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2011 | 215 | 0.520 |
Why?
|
| Anti-Retroviral Agents | 2 | 2015 | 147 | 0.510 |
Why?
|
| Mutation | 4 | 2017 | 1095 | 0.490 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2018 | 234 | 0.490 |
Why?
|
| Fatty Acids | 1 | 2015 | 127 | 0.470 |
Why?
|
| Science | 1 | 2013 | 18 | 0.460 |
Why?
|
| Career Choice | 1 | 2013 | 45 | 0.450 |
Why?
|
| Cytokines | 4 | 2015 | 602 | 0.430 |
Why?
|
| Humans | 38 | 2018 | 37093 | 0.360 |
Why?
|
| Scleroderma, Systemic | 1 | 2010 | 11 | 0.360 |
Why?
|
| Equipment Reuse | 1 | 2009 | 3 | 0.340 |
Why?
|
| Female | 30 | 2017 | 20969 | 0.340 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2011 | 221 | 0.340 |
Why?
|
| Male | 29 | 2017 | 20025 | 0.330 |
Why?
|
| Adult | 23 | 2015 | 11712 | 0.330 |
Why?
|
| Drug Tolerance | 2 | 2008 | 40 | 0.330 |
Why?
|
| Drug Users | 1 | 2009 | 46 | 0.320 |
Why?
|
| Drug Compounding | 1 | 2009 | 76 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2010 | 864 | 0.320 |
Why?
|
| Methadone | 1 | 2008 | 19 | 0.320 |
Why?
|
| Narcotics | 1 | 2008 | 32 | 0.310 |
Why?
|
| Th2 Cells | 2 | 2006 | 58 | 0.300 |
Why?
|
| Morphine | 1 | 2008 | 85 | 0.300 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 803 | 0.300 |
Why?
|
| Heroin Dependence | 1 | 2006 | 23 | 0.290 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 16 | 0.280 |
Why?
|
| Chemokine CCL5 | 1 | 2006 | 39 | 0.280 |
Why?
|
| Risk-Taking | 4 | 2015 | 451 | 0.280 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 85 | 0.270 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 29 | 0.260 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 155 | 0.250 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 259 | 0.250 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2015 | 34 | 0.250 |
Why?
|
| Middle Aged | 14 | 2015 | 10129 | 0.250 |
Why?
|
| Macrophages | 1 | 2008 | 439 | 0.240 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 5 | 0.240 |
Why?
|
| Dermatomyositis | 1 | 2004 | 7 | 0.240 |
Why?
|
| Cardiac Tamponade | 1 | 2004 | 4 | 0.240 |
Why?
|
| HIV | 2 | 2006 | 98 | 0.230 |
Why?
|
| Hepacivirus | 2 | 2006 | 62 | 0.210 |
Why?
|
| Adolescent | 12 | 2015 | 5363 | 0.210 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 1067 | 0.210 |
Why?
|
| Cells, Cultured | 4 | 2018 | 1518 | 0.200 |
Why?
|
| Cross-Sectional Studies | 8 | 2014 | 2721 | 0.200 |
Why?
|
| Prevalence | 6 | 2010 | 1455 | 0.200 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2013 | 189 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2002 | 357 | 0.180 |
Why?
|
| Cohort Studies | 6 | 2015 | 1492 | 0.180 |
Why?
|
| Sex Factors | 3 | 2015 | 898 | 0.170 |
Why?
|
| Immunologic Factors | 2 | 2015 | 45 | 0.160 |
Why?
|
| Time Factors | 3 | 2015 | 1742 | 0.160 |
Why?
|
| Chemokines | 1 | 2018 | 97 | 0.150 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2015 | 56 | 0.150 |
Why?
|
| Age Factors | 2 | 2015 | 1033 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2015 | 661 | 0.150 |
Why?
|
| Adolescent Behavior | 3 | 2015 | 253 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 4 | 2015 | 107 | 0.140 |
Why?
|
| DNA, Superhelical | 1 | 2015 | 7 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2015 | 2379 | 0.130 |
Why?
|
| Alkynes | 1 | 2015 | 50 | 0.130 |
Why?
|
| Smallpox | 1 | 2015 | 1 | 0.130 |
Why?
|
| Variola virus | 1 | 2015 | 1 | 0.130 |
Why?
|
| Smallpox Vaccine | 1 | 2015 | 2 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 352 | 0.130 |
Why?
|
| Stomatitis | 1 | 2014 | 2 | 0.130 |
Why?
|
| School Health Services | 1 | 2015 | 81 | 0.130 |
Why?
|
| Mouth | 1 | 2014 | 45 | 0.120 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 38 | 0.120 |
Why?
|
| Young Adult | 3 | 2015 | 4268 | 0.120 |
Why?
|
| Risk Factors | 5 | 2015 | 3562 | 0.120 |
Why?
|
| Gram-Positive Bacteria | 1 | 2013 | 14 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2013 | 27 | 0.120 |
Why?
|
| Gram-Negative Bacteria | 1 | 2013 | 22 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2013 | 42 | 0.110 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 730 | 0.110 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 1989 | 19 | 0.110 |
Why?
|
| Aged | 4 | 2015 | 6741 | 0.100 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 9 | 0.100 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 41 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2010 | 18 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 225 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 336 | 0.090 |
Why?
|
| Raynaud Disease | 1 | 2010 | 7 | 0.090 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2010 | 113 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 105 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 55 | 0.090 |
Why?
|
| Cimetidine | 1 | 1989 | 1 | 0.090 |
Why?
|
| Cyclosporins | 1 | 1989 | 2 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 147 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 854 | 0.090 |
Why?
|
| Syringes | 1 | 2009 | 6 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2010 | 150 | 0.080 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 35 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2010 | 61 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 1989 | 89 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2015 | 1378 | 0.080 |
Why?
|
| Ethanol | 1 | 2010 | 192 | 0.080 |
Why?
|
| Minority Groups | 1 | 2013 | 596 | 0.080 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2231 | 0.080 |
Why?
|
| Students | 1 | 2013 | 519 | 0.080 |
Why?
|
| Naloxone | 1 | 2008 | 52 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 57 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 93 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 2 | 1998 | 90 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2009 | 339 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1398 | 0.070 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2008 | 107 | 0.070 |
Why?
|
| Genotype | 2 | 2017 | 730 | 0.070 |
Why?
|
| Chemokine CCL3 | 1 | 2006 | 14 | 0.070 |
Why?
|
| Chemokine CCL4 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2006 | 38 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2006 | 68 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2006 | 92 | 0.070 |
Why?
|
| Mortality | 2 | 2005 | 145 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 550 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 448 | 0.070 |
Why?
|
| Community-Based Participatory Research | 1 | 2009 | 317 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2006 | 859 | 0.060 |
Why?
|
| CD4-CD8 Ratio | 2 | 2002 | 30 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1039 | 0.060 |
Why?
|
| Hospitals | 1 | 2005 | 86 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2005 | 32 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2008 | 587 | 0.060 |
Why?
|
| Prednisone | 1 | 2004 | 27 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2004 | 14 | 0.060 |
Why?
|
| Comorbidity | 3 | 2014 | 623 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 62 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2005 | 238 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 885 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 224 | 0.060 |
Why?
|
| Infant | 2 | 2005 | 1046 | 0.060 |
Why?
|
| Pneumonia | 1 | 2003 | 54 | 0.060 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2002 | 18 | 0.050 |
Why?
|
| Social Class | 1 | 2005 | 247 | 0.050 |
Why?
|
| Endopeptidases | 1 | 2002 | 59 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2005 | 894 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2005 | 1418 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 149 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 159 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2002 | 399 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2001 | 195 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1198 | 0.050 |
Why?
|
| Disease Progression | 1 | 2002 | 601 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2001 | 301 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2004 | 1369 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 18 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1998 | 18 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 1998 | 28 | 0.040 |
Why?
|
| Child | 2 | 2005 | 3131 | 0.040 |
Why?
|
| Plants, Medicinal | 1 | 1998 | 68 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 1998 | 132 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1997 | 26 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1103 | 0.040 |
Why?
|
| HIV Protease | 1 | 2017 | 21 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2013 | 201 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 1997 | 76 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 1997 | 236 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Vero Cells | 1 | 2015 | 93 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2015 | 16 | 0.030 |
Why?
|
| Plant Extracts | 1 | 1998 | 286 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2015 | 31 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2015 | 43 | 0.030 |
Why?
|
| Mice | 4 | 2015 | 5913 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2015 | 24 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2015 | 72 | 0.030 |
Why?
|
| Animals | 5 | 2015 | 15081 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 70 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 61 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 75 | 0.030 |
Why?
|
| Prisoners | 1 | 2014 | 83 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2014 | 304 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 262 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2014 | 190 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2015 | 453 | 0.030 |
Why?
|
| Alcoholism | 1 | 2014 | 240 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 29 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1371 | 0.020 |
Why?
|
| HTLV-I Antibodies | 1 | 1989 | 7 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 212 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2014 | 609 | 0.020 |
Why?
|
| Proteome | 1 | 2010 | 144 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2014 | 583 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 1989 | 92 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 441 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 1989 | 1609 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 674 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 325 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 385 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 485 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2003 | 14 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 131 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2010 | 642 | 0.010 |
Why?
|
| Hypertension | 1 | 2010 | 796 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 922 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1998 | 21 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 46 | 0.010 |
Why?
|
| Artemia | 1 | 1998 | 16 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 60 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 65 | 0.010 |
Why?
|
| Mycobacterium | 1 | 1998 | 15 | 0.010 |
Why?
|
| Biological Assay | 1 | 1998 | 59 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1998 | 112 | 0.010 |
Why?
|
| Influenza Vaccines | 1 | 1997 | 55 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1997 | 125 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 1989 | 31 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1989 | 63 | 0.010 |
Why?
|